The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection

Launched by AIN SHAMS UNIVERSITY · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a medication called Albendazole after surgery to remove pulmonary hydatid cysts, which are fluid-filled sacs in the lungs caused by a parasitic infection. The main goal is to see if taking Albendazole after the surgery can help prevent the cysts from coming back compared to a placebo (a dummy treatment) over a follow-up period of six months.

Anyone with pulmonary hydatid disease who needs surgery may be eligible to participate, as long as they have had a complete removal of the cysts and have not experienced any other related health issues. Participants will receive either Albendazole or a placebo after their surgery and will be monitored for any signs of recurrence. It's important to note that patients with certain conditions, like other types of hydatid disease or liver problems, cannot join the study. This trial is currently recruiting participants of all ages and genders, aiming to gather important information about the effectiveness of Albendazole in preventing the return of these cysts after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All patients regardless of age with pulmonary hydatid disease requiring surgical resection.
• • 2. Patients achieving complete resection of pulmonary hydatid disease.
• • 3. Patients with no extra pulmonary hydatid disease.
• • 4. Patients who have received preoperative albendazole.
• Exclusion Criteria:
• • 1. Patients with extra pulmonary hydatid disease requiring treatment after pulmonary resection.
• • 2. Patients with incomplete resection of pulmonary hydatid disease.
• • 3. Patients with pulmonary hydatid disease not amenable for resection.
• • 4. Patients with hypersensitivity to Albendazole.
• • 5. Patients with liver dysfunction.
• • 6. Patients refusing to be enrolled in the study.